HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: HDAC class IIb inhibitors (bufexamac) sensitized neuroblastoma cells to drug‐induced cell death by inhibiting autophagy.46 The HDAC inhibitors suberoylanilide hydroxamic acid (SAHA)/vorinostat and romidepsin have already been approved by FDA for the treatment of cutaneous T cell lymphoma.